CYP-001 GvHD Trial Primary Evaluation Results
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The trial showed no safety concerns, but the primary and key secondary endpoints did not demonstrate significant differences between the treatment and control groups. As a result of these findings, the company has decided to terminate the trial early.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Cynata Therapeutics Limited on 6ix
Earlier from Cynata Therapeutics
- Suspension from Quotation
- EU Positive Opinion on CYP-001 Paediatric Investigation Plan
- Cynata Secures Commitments for $1.5m Placement
- March 2026 Quarterly Activity Report & Appendix 4C
- Last Visit in GvHD Trial Completed
Later from Cynata Therapeutics
- Reinstatement to Official Quotation
- Board, Management Changes, Expenditure Reductions, RDTI Loan
- June 2026 Quarterly Activity Report & Appendix 4C
- Appendix 4E & Preliminary Final Report
- Notification under Listing Rule 4.3D
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics